On November 12, 2020 Sierra Oncology, Inc. (SRRA), a late-stage biopharmaceutical company focused on the Phase 3 execution, registration and potential commercialization of momelotinib, a novel drug that may address serious unmet needs in myelofibrosis, reported that President and Chief Executive Officer Stephen Dilly, MBBS, PhD, will present an overview of the company at the Jefferies Virtual London Healthcare Conference taking place November 17-19, 2020 (Press release, Sierra Oncology, NOV 12, 2020, View Source [SID1234570760]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation is scheduled for 7:20 pm GMT on Wednesday, November 18. A replay of the presentation will be available following the conference on the Investors section of Sierra’s corporate website in the Events & Webcast tab.